We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

StemCells Inc. Receives FDA Approval to Initiate Clinical Trial of HuCNS-SC® Cells in a Myelin Disease

The Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for Pelizaeus-Merzbacher Disease.
News

VistaGen and WARF Sign License Agreement for Human Embryonic Stem Cell Technology

The license is expected to accelerate Vistagen’s commercial programs focused on stem cell-based ‘clinical trials in a Test Tube™.
News

Sucampo Initiates Phase 1 Study of SPL-017 for Peripheral Arterial Disease

The randomized, double-blind, placebo-controlled, single-center, single ascending dose study will evaluate the safety and pharmacokinetic profile of SPL-017.
News

Abbott Exercises its Option to Acquire IBIS Biosciences, a Subsidiary of ISIS

The acquisition worth $215 million will expand Abbott's position in molecular diagnostics for infectious disease.
News

FDA Signs Contract with Entelos to Predict Cardiovascular Adverse Events

FDA to use the Entelos® Cardiovascular PhysioLab® to assess the cardiovascular safety and efficacy of a specific drug class and a set of drugs within that class.
News

GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance

The collaboration is aimed at developing first-in-class endosomal Toll-like Receptors inhibitors for autoimmune and inflammatory diseases.
News

Horizon Discovery Sign Screening Agreement with Actelion Pharmaceuticals

The agreement covers the screening of a number of Actelion lead compounds on a wide panel of genotypes using Horizon’s X-MAN cell-line technology.
News

Mouse Studies Show Gene Therapy Method Holds Promise in Targeting Tumor Blood Vessels for Destruction

Cancer researchers develop method for delivering a therapeutic gene specifically to the blood vessels of tumors in mice.
News

Yissum Subsidiary Jexys Announces Research and Development Collaboration Agreement with Teva

Teva to finance Jexys' R&D program for the development of a high throughput drug discovery platform and in return will receive a minority equity interest in Jexys.
News

Life Sciences Discovery Fund Awards Health Research Program Grants

The newly-funded health research initiatives will focus on advancing vaccine development and developing highly-targeted intracellular drug delivery mechanisms.
Advertisement